Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tree SLIT-tablet placebo-controlled efficacy trial in adolescents with birch pollen allergic rhinitis
2026-526861-88-00Phase 4Authorised
- Sponsor
- ALK-Abelló
- Start
- Oct 2026
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing Tree SLIT-tablet with Placebo to tree SLIT-tablet (2 arms). Primary endpoint: Average total symptom score from hours 2 to 4 during the 4-hour birch efficacy EEU session. Planned start Oct 2026; status: authorised.
02
Drugs
birch pollen allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2026-526861-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526861-88-00.